Peter John Fellner

Peter John Fellner currently works at Ligand UK Development Ltd., as Director.
Dr. Fellner also formerly worked at Roche Holding (UK) Ltd., as Chief Executive Officer from 1986 to 1990, Ligand UK Ltd., as Non-Executive Chairman from 2012 to 2018, Celltech Group Plc, as Chairman from 2003 to 2004, Acambis Plc, as Chairman from 2006 to 2008, Consort Medical Ltd., as Non-Executive Chairman from 2009 to 2019, Premier Research Group Ltd., as Non-Executive Chairman, Ionix Pharmaceuticals Ltd., as Chairman, Astex Therapeutics Ltd., as Chairman from 2002 to 2011, Optos Plc, as Non-Executive Chairman from 2012 to 2015, Ablynx NV, as Chairman from 2013 to 2018, Astex Pharmaceuticals, Inc., as Vice Chairman from 2011 to 2013, Mereo BioPharma Group Plc, as Vice Chairman in 2022, QinetiQ Group plc, as Director from 2004 to 2009, UCB SA, as Independent Non-Executive Director from 2012 to 2014, Evotec SE, as Non-Executive Director in 2011, Biotie Therapies Oy, as Director from 2009 to 2010, QinetiQ Ltd., as Non-Executive Director, and The Medical Research Council, as Member from 2000 to 2007.
Dr. Fellner received his doctorate degree from the University of Cambridge and undergraduate degree from The University of Sheffield.